Back to home

Posts from "Hematology" tag

How a Hematology Clinical Rotation Made me a Better Clinician

Rory Medley, PA-S Rory Medley, PA-S

Starting physician assistant (PA) school certainly presented its obstacles. How would I, a fresh college graduate, be able to tackle an intense medical education within the span of 27 months? The answer was almost too simple – one semester at a time. Fifteen months of didactic education came and ...

Read more

Recent Updates in the Treatment of Chronic-Graft-Versus-Host Disease

Fatima Khan, PharmD & Ila M. Saunders, PharmD, BCOP Fatima Khan, PharmD & Ila M. Saunders, PharmD, BCOP

Chronic graft-versus-host disease (cGVHD) is one of most common, yet severe, consequences of allogeneic hematopoietic stem cell transplantation. Occurring in up to 70% of patients, cGVHD is the leading cause of non-relapse mortality after allogeneic transplantation. Two new agents, belumosudil ...

Read more

Disease, Drugs and Infection: A Systematic Assessment of the Malignant Hematology Patient

Glen J Peterson, RN, DNP, ACNP & Jessica Casselberry, MSN, ANP-BC, AOCNP Glen J Peterson, RN, DNP, ACNP & Jessica Casselberry, MSN, ANP-BC, AOCNP

A thorough assessment of the patient with a hematologic malignancy is essential for the delivery of quality care. Almost every medical condition, symptom or complication will be caused by the patient’s underlying disease, a medication they have been prescribed, or an infection. Taking time to ...

Read more

A Proven Strategy of Targeted Therapy: Antibody Drug Conjugates in Cancer Treatment

Samantha Musson, PharmD & Moe Schwartz, PharmD, BCOP Samantha Musson, PharmD & Moe Schwartz, PharmD, BCOP

The term “targeted therapy” in cancer refers to drugs or treatment strategies that direct anticancer treatment to specific genes or proteins that influence the growth, proliferation and/or survival of cancer cells.   Antibody-drug conjugates (ADC) are a targeted strategy that has rapidly evolved in ...

Read more

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2)

Adam Kahleifeh, PharmD Adam Kahleifeh, PharmD

Multiple myeloma (MM) is a neoplasm characterized by the clonal proliferation of plasma cells that remains an incurable disease. The treatment of relapsed or relapsed/refractory MM continues to be a challenge despite numerous therapeutic advances. B-cell maturation antigen (BCMA) is a cell-surface ...

Read more

Categorizing “Chemo”

Tyler Redelico, PharmD, BCOP & Christina Zelasko, PharmD, BCPS Tyler Redelico, PharmD, BCOP & Christina Zelasko, PharmD, BCPS

Both health care professionals and patients regularly refer to systemic oncology treatments as “chemo”, although every month this term becomes less representative. Some medications clearly fit into certain categories: cisplatin & methotrexate (traditional chemotherapy), imatinib & ...

Read more